Open AccessPrescribe an SGLT2 inhibitor for heart failure in the absence of diabetes?
Author(s) -
Debra Koenigsberger,
Alexander Marquez,
Pamela Hughes,
Rebecca Mullen
Publication year - 2021
Publication title -
the journal of family practice
Language(s) - English
Resource type - Journals
eISSN - 1533-7294
DOI - 10.12788/jfp.0235
Subject(s) - medicine , diabetes mellitus , heart failure , intensive care medicine , endocrinology
An RCT demonstrates that dapagliflozin produces better cardiovascular outcomes than placebo for heart failure patients with and without diabetes.